Myomo Inc. has released a new investor presentation outlining its strategic positioning in the wearable medical robotics market. The company highlights the MyoPro myoelectric orthosis as a first-mover in addressing upper limb paralysis caused by conditions such as stroke, nerve injury, and neurological diseases. The presentation details recent developments in insurance reimbursement, including expanded access through Medicare Part B and approvals from health insurance providers in Germany and Australia. Myomo also discusses its direct provider business and new distribution channels, noting that Medicare Advantage plans are now required to follow Medicare coverage guidelines. Updated reimbursement rates for the MyoPro under HCPCS codes L8701 and L8702 are included, with effective fees set for January 2025. The company identifies a substantial market opportunity due to an expanded addressable population and ongoing global reimbursement efforts. You can access the full presentation through the link below.